Generative AI is transforming drug optimization by accelerating analog design, improving ADMET predictions, and automating synthesis planning. Traditionally taking 12–24 months, this phase can now be shortened by up to 50%, with cost savings of 30–40%. From analog generation to compound prioritization, Gen AI enables faster, smarter decisions—empowering teams and reshaping the future of drug development.